These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9873490)

  • 1. Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers.
    Dreef-Tromp CM; Basten JE; Broekhoven MA; van Dinther TG; Petitou M; van Boeckel CA
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2081-6. PubMed ID: 9873490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of synthetic heparin-like conjugates comprising different thrombin binding domains.
    Basten JE; Dreef-Tromp CM; de Wijs B; van Boeckel CA
    Bioorg Med Chem Lett; 1998 May; 8(10):1201-6. PubMed ID: 9871735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity.
    Grootenhuis PD; Westerduin P; Meuleman D; Petitou M; van Boeckel CA
    Nat Struct Biol; 1995 Sep; 2(9):736-9. PubMed ID: 7552742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
    Walenga JM; Jeske WP; Bara L; Samama MM; Fareed J
    Thromb Res; 1997 Apr; 86(1):1-36. PubMed ID: 9172284
    [No Abstract]   [Full Text] [Related]  

  • 6. New synthetic heparin mimetics able to inhibit thrombin and factor Xa.
    Petitou M; Duchaussoy P; Driguez PA; Hérault JP; Lormeau JC; Herbert JM
    Bioorg Med Chem Lett; 1999 Apr; 9(8):1155-60. PubMed ID: 10328304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of thrombin-inhibiting heparin mimetics without side effects.
    Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
    Nature; 1999 Apr; 398(6726):417-22. PubMed ID: 10201371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sugars slide into heparin activity.
    Sinaÿ P
    Nature; 1999 Apr; 398(6726):377-8. PubMed ID: 10201366
    [No Abstract]   [Full Text] [Related]  

  • 9. SR123781A, a synthetic heparin mimetic.
    Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
    Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [From heparin to synthetic antithrombotic oligosaccharides].
    Petitou M
    Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of thrombin inactivation by immobilized heparin.
    Byun Y; Jacobs HA; Kim SW
    J Biomed Mater Res; 1996 Apr; 30(4):423-7. PubMed ID: 8847350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of heparin immobilized "side-on" to polystyrene microspheres coated with end-group activated polyethylene oxide.
    Joshi P; Schilke KF; Fry A; McGuire J; Bird K
    Int J Biol Macromol; 2010 Aug; 47(2):98-103. PubMed ID: 20621768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
    Petitou M; van Boeckel CA
    Angew Chem Int Ed Engl; 2004 Jun; 43(24):3118-33. PubMed ID: 15199558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics.
    Petitou M; Driguez PA; Duchaussoy P; Hérault JP; Lormeau JC; Herbert JM
    Bioorg Med Chem Lett; 1999 Apr; 9(8):1161-6. PubMed ID: 10328305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin, carboxyl-reduced sulfated heparin, and Trestatin A sulfate. Antiproliferative and anticoagulant activities.
    Wessel HP; Hosang M; Tschopp TB; Weimann BJ
    Carbohydr Res; 1990 Sep; 204():131-9. PubMed ID: 2279243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics.
    Masuko S; Linhardt RJ
    Future Med Chem; 2012 Mar; 4(3):289-96. PubMed ID: 22393937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities.
    Vogel GM; van Amsterdam RG; van Dinther TG; Tromp M; Meuleman DG
    Thromb Haemost; 2000 Oct; 84(4):611-20. PubMed ID: 11057859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and biological interactions of heparin and heparan sulfate.
    Casu B; Lindahl U
    Adv Carbohydr Chem Biochem; 2001; 57():159-206. PubMed ID: 11836942
    [No Abstract]   [Full Text] [Related]  

  • 19. Dracula's wish.
    Peters R; Sikorski R
    Science; 1999 May; 284(5418):1294. PubMed ID: 10383310
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition.
    Duchaussoy P; Jaurand G; Driguez PA; Lederman I; Ceccato ML; Gourvenec F; Strassel JM; Sizun P; Petitou M; Herbert JM
    Carbohydr Res; 1999 Apr; 317(1-4):85-99. PubMed ID: 10466208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.